Canada
· Delayed Price · Currency is CAD Aequus Pharmaceuticals Statistics
Total Valuation
TSXV:AQS has a market cap or net worth of CAD 663,172. The enterprise value is 7.23 million.
| Market Cap | 663,172 |
| Enterprise Value | 7.23M |
Important Dates
The next estimated earnings date is Friday, August 29, 2025.
| Earnings Date | Aug 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:AQS has 132.63 million shares outstanding.
| Current Share Class | 132.63M |
| Shares Outstanding | 132.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.68% |
| Owned by Institutions (%) | n/a |
| Float | 113.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| PB Ratio | -0.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.34 |
| EV / Sales | 9.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.92 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -143.59% |
| Return on Invested Capital (ROIC) | -1,021.41% |
| Return on Capital Employed (ROCE) | 24.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 12 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 2.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.00% in the last 52 weeks. The beta is -0.13, so TSXV:AQS's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -75.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 46.71 |
| Average Volume (20 Days) | 5,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TSXV:AQS had revenue of CAD 758,227 and -2.16 million in losses. Loss per share was -0.02.
| Revenue | 758,227 |
| Gross Profit | 433,797 |
| Operating Income | -1.60M |
| Pretax Income | -2.16M |
| Net Income | -2.16M |
| EBITDA | n/a |
| EBIT | -1.60M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 39,169 in cash and 6.58 million in debt, giving a net cash position of -6.54 million or -0.05 per share.
| Cash & Cash Equivalents | 39,169 |
| Total Debt | 6.58M |
| Net Cash | -6.54M |
| Net Cash Per Share | -0.05 |
| Equity (Book Value) | -7.11M |
| Book Value Per Share | -0.05 |
| Working Capital | -6.69M |
Cash Flow
| Operating Cash Flow | -1.10M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 57.21%, with operating and profit margins of -211.57% and -284.96%.
| Gross Margin | 57.21% |
| Operating Margin | -211.57% |
| Pretax Margin | -284.96% |
| Profit Margin | -284.96% |
| EBITDA Margin | n/a |
| EBIT Margin | -211.57% |
| FCF Margin | n/a |
Dividends & Yields
TSXV:AQS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -325.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TSXV:AQS has an Altman Z-Score of -204.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -204.52 |
| Piotroski F-Score | 2 |